- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book provides an introduction to depression, including common comorbid conditions and differential diagnoses, treatment strategies, and considerations in special populations.
Andere Kunden interessierten sich auch für
- Robert FergusonMemory and Attention Adaptation Training29,99 €
- Joel ParisPrescriptions for the Mind71,99 €
- Stephen M StrakowskiBipolar Disorder153,99 €
- Clinical Psychology in the Mental Health Inpatient Setting71,99 €
- Depression and Type 2 Diabetes80,99 €
- Depression as a Systemic Illness102,99 €
- Video and Filmmaking as Psychotherapy62,99 €
-
-
-
This book provides an introduction to depression, including common comorbid conditions and differential diagnoses, treatment strategies, and considerations in special populations.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Oxford University Press
- Seitenzahl: 520
- Erscheinungstermin: 22. November 2019
- Englisch
- Abmessung: 251mm x 177mm x 30mm
- Gewicht: 921g
- ISBN-13: 9780190929565
- ISBN-10: 0190929561
- Artikelnr.: 57975764
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
- Verlag: Oxford University Press
- Seitenzahl: 520
- Erscheinungstermin: 22. November 2019
- Englisch
- Abmessung: 251mm x 177mm x 30mm
- Gewicht: 921g
- ISBN-13: 9780190929565
- ISBN-10: 0190929561
- Artikelnr.: 57975764
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
Madhukar Trivedi is Professor of Psychiatry, Chief of the Division of Mood Disorders, and Founding Director of the Center for Depression Research and Clinical Care at UT Southwestern Medical Center. He is an internationally recognized translational researcher focusing on developing and validating biosignatures of depression. He specializes in treating depression and conducts research on pharmacological, psychosocial, and nonpharmacological treatments for depression, including ketamine, magnetic stimulation, and exercise. Holding the Betty Ho Hay Distinguished Chair in Mental Health and the Julie K. Hersh Chair for Depression Research and Clinical Care at UTSW, Dr. Trivedi has received numerous accolades, including the Psychiatric Excellence Award from the Texas Society of Psychiatric Physicians and the Gerald Klerman Senior Investigator Award from the Depression and Bipolar Support Alliance. With over 500 articles and chapters related to the diagnosis and treatment of mood disorders, Dr. Trivedi was listed on Thomas Reuters' World's Most Influential Scientific Minds in each year since 2014 as one of the most highly cited researchers in the U.S. field of Psychiatry. Series editor: Steven M. Strakowski, MD, Founding Chair, Department of Psychiatry, Dell Medical School, University of Texas, Austin
1.Introduction and Overview
I. Etiology/Pathophysiology
2. Neurobiology
3. Genetic Risk Factors
4. Environmental and Social Risk Factors
5. Blood-based Biomarkers
II. Comorbidities and Differential Diagnoses
6. Anxiety Disorders
7. Bipolar Disorder
8. Suicidality
9. General Medical Conditions
10. General Medical Conditions, Metabolic Disorders
III. Pharmacotherapy for Depression
11. First line and combination therapeutics
12. Augmentation strategies
13. Rapid-acting antidepressants
14. Side Effects of Antidepressant
15. Strategies for targeting residual symptoms
IV. Psychotherapy and modalities of delivery for Depression
16. Cognitive Behavioral Therapy/Behavioral Activation
17. Behavioral Activation for Depression
18. Psychodynamic and Supportive Psychotherapy
19. ECT/TMS
V. Novel, Non-Traditional Treatment Strategies for Depression
20. Exercise as a treatment for depression
21. Therapeutic Mindfulness For Relapse Prophylaxis in Unipolar Depression
22. Probiotics and Neutraceuticals
23. Chronobiological Treatments: Sleep and Light Therapies
VI. Special Populations in Depression
24. Children and Adolescents
25. Elderly Patients
26. Pregnant and Postpartum
27. Depression Following Mild Traumatic Brain Injury
28. Treatment in Primary Care
VII. MISCELLANEOUS
29. Future Directions: Precision Medicine and Biosignatures
I. Etiology/Pathophysiology
2. Neurobiology
3. Genetic Risk Factors
4. Environmental and Social Risk Factors
5. Blood-based Biomarkers
II. Comorbidities and Differential Diagnoses
6. Anxiety Disorders
7. Bipolar Disorder
8. Suicidality
9. General Medical Conditions
10. General Medical Conditions, Metabolic Disorders
III. Pharmacotherapy for Depression
11. First line and combination therapeutics
12. Augmentation strategies
13. Rapid-acting antidepressants
14. Side Effects of Antidepressant
15. Strategies for targeting residual symptoms
IV. Psychotherapy and modalities of delivery for Depression
16. Cognitive Behavioral Therapy/Behavioral Activation
17. Behavioral Activation for Depression
18. Psychodynamic and Supportive Psychotherapy
19. ECT/TMS
V. Novel, Non-Traditional Treatment Strategies for Depression
20. Exercise as a treatment for depression
21. Therapeutic Mindfulness For Relapse Prophylaxis in Unipolar Depression
22. Probiotics and Neutraceuticals
23. Chronobiological Treatments: Sleep and Light Therapies
VI. Special Populations in Depression
24. Children and Adolescents
25. Elderly Patients
26. Pregnant and Postpartum
27. Depression Following Mild Traumatic Brain Injury
28. Treatment in Primary Care
VII. MISCELLANEOUS
29. Future Directions: Precision Medicine and Biosignatures
1.Introduction and Overview
I. Etiology/Pathophysiology
2. Neurobiology
3. Genetic Risk Factors
4. Environmental and Social Risk Factors
5. Blood-based Biomarkers
II. Comorbidities and Differential Diagnoses
6. Anxiety Disorders
7. Bipolar Disorder
8. Suicidality
9. General Medical Conditions
10. General Medical Conditions, Metabolic Disorders
III. Pharmacotherapy for Depression
11. First line and combination therapeutics
12. Augmentation strategies
13. Rapid-acting antidepressants
14. Side Effects of Antidepressant
15. Strategies for targeting residual symptoms
IV. Psychotherapy and modalities of delivery for Depression
16. Cognitive Behavioral Therapy/Behavioral Activation
17. Behavioral Activation for Depression
18. Psychodynamic and Supportive Psychotherapy
19. ECT/TMS
V. Novel, Non-Traditional Treatment Strategies for Depression
20. Exercise as a treatment for depression
21. Therapeutic Mindfulness For Relapse Prophylaxis in Unipolar Depression
22. Probiotics and Neutraceuticals
23. Chronobiological Treatments: Sleep and Light Therapies
VI. Special Populations in Depression
24. Children and Adolescents
25. Elderly Patients
26. Pregnant and Postpartum
27. Depression Following Mild Traumatic Brain Injury
28. Treatment in Primary Care
VII. MISCELLANEOUS
29. Future Directions: Precision Medicine and Biosignatures
I. Etiology/Pathophysiology
2. Neurobiology
3. Genetic Risk Factors
4. Environmental and Social Risk Factors
5. Blood-based Biomarkers
II. Comorbidities and Differential Diagnoses
6. Anxiety Disorders
7. Bipolar Disorder
8. Suicidality
9. General Medical Conditions
10. General Medical Conditions, Metabolic Disorders
III. Pharmacotherapy for Depression
11. First line and combination therapeutics
12. Augmentation strategies
13. Rapid-acting antidepressants
14. Side Effects of Antidepressant
15. Strategies for targeting residual symptoms
IV. Psychotherapy and modalities of delivery for Depression
16. Cognitive Behavioral Therapy/Behavioral Activation
17. Behavioral Activation for Depression
18. Psychodynamic and Supportive Psychotherapy
19. ECT/TMS
V. Novel, Non-Traditional Treatment Strategies for Depression
20. Exercise as a treatment for depression
21. Therapeutic Mindfulness For Relapse Prophylaxis in Unipolar Depression
22. Probiotics and Neutraceuticals
23. Chronobiological Treatments: Sleep and Light Therapies
VI. Special Populations in Depression
24. Children and Adolescents
25. Elderly Patients
26. Pregnant and Postpartum
27. Depression Following Mild Traumatic Brain Injury
28. Treatment in Primary Care
VII. MISCELLANEOUS
29. Future Directions: Precision Medicine and Biosignatures